Sanofi (SNYNF)
USD 98.65
(0.0%)
USD 98.65
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 5.4 Billion EUR | -35.49% |
| 2022 | 8.37 Billion EUR | 34.52% |
| 2021 | 6.22 Billion EUR | -49.38% |
| 2020 | 12.29 Billion EUR | 338.13% |
| 2019 | 2.8 Billion EUR | -34.84% |
| 2018 | 4.3 Billion EUR | -48.94% |
| 2017 | 8.43 Billion EUR | 79.1% |
| 2016 | 4.7 Billion EUR | 9.84% |
| 2015 | 4.28 Billion EUR | -2.35% |
| 2014 | 4.39 Billion EUR | 18.11% |
| 2013 | 3.71 Billion EUR | -25.17% |
| 2012 | 4.96 Billion EUR | -12.75% |
| 2011 | 5.69 Billion EUR | 4.13% |
| 2010 | 5.46 Billion EUR | 3.84% |
| 2009 | 5.26 Billion EUR | -26.73% |
| 2008 | 7.18 Billion EUR | 36.32% |
| 2007 | 5.27 Billion EUR | 31.6% |
| 2006 | 4 Billion EUR | 77.57% |
| 2005 | 2.25 Billion EUR | 162.54% |
| 2004 | -3.6 Billion EUR | -274.06% |
| 2003 | 2.07 Billion EUR | 17.74% |
| 2002 | 1.76 Billion EUR | 11.05% |
| 2001 | 1.58 Billion EUR | 60.91% |
| 2000 | 985 Million EUR | 57.6% |
| 1999 | 625 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 2.81 Billion EUR | 25.33% |
| 2024 Q1 | 1.13 Billion EUR | -42.49% |
| 2024 Q2 | 2.24 Billion EUR | 98.23% |
| 2023 Q3 | 2.52 Billion EUR | 75.96% |
| 2023 Q4 | 1.97 Billion EUR | -21.98% |
| 2023 Q1 | 1.99 Billion EUR | 36.64% |
| 2023 FY | 5.4 Billion EUR | -35.49% |
| 2023 Q2 | 1.43 Billion EUR | -28.07% |
| 2022 Q1 | 2 Billion EUR | 77.63% |
| 2022 Q2 | 1.17 Billion EUR | -41.51% |
| 2022 Q3 | 2.07 Billion EUR | 76.68% |
| 2022 Q4 | 1.46 Billion EUR | -29.67% |
| 2022 FY | 8.37 Billion EUR | 34.52% |
| 2021 Q2 | 1.21 Billion EUR | -22.73% |
| 2021 Q3 | 2.31 Billion EUR | 91.49% |
| 2021 Q4 | 1.13 Billion EUR | -51.19% |
| 2021 FY | 6.22 Billion EUR | -49.38% |
| 2021 Q1 | 1.56 Billion EUR | 44.87% |
| 2020 Q1 | 1.68 Billion EUR | 16930.0% |
| 2020 Q2 | 7.59 Billion EUR | 351.46% |
| 2020 Q3 | 1.95 Billion EUR | -74.31% |
| 2020 FY | 12.29 Billion EUR | 338.13% |
| 2020 Q4 | 1.08 Billion EUR | -44.62% |
| 2019 Q2 | -87 Million EUR | -107.65% |
| 2019 Q1 | 1.13 Billion EUR | 347.64% |
| 2019 FY | 2.8 Billion EUR | -34.84% |
| 2019 Q4 | -10 Million EUR | -100.57% |
| 2019 Q3 | 1.76 Billion EUR | 2129.89% |
| 2018 Q1 | 1.01 Billion EUR | 687.6% |
| 2018 Q2 | 762 Million EUR | -25.0% |
| 2018 Q3 | 2.27 Billion EUR | 198.43% |
| 2018 Q4 | 254 Million EUR | -88.83% |
| 2018 FY | 4.3 Billion EUR | -48.94% |
| 2017 Q1 | 5.7 Billion EUR | 621.65% |
| 2017 Q3 | 1.56 Billion EUR | 51.11% |
| 2017 Q4 | 129 Million EUR | -91.77% |
| 2017 FY | 8.43 Billion EUR | 79.1% |
| 2017 Q2 | 1.03 Billion EUR | -81.81% |
| 2016 FY | 4.7 Billion EUR | 9.84% |
| 2016 Q2 | 1.15 Billion EUR | 6.53% |
| 2016 Q1 | 1.08 Billion EUR | 225.45% |
| 2016 Q4 | 790 Million EUR | -52.81% |
| 2016 Q3 | 1.67 Billion EUR | 44.56% |
| 2015 Q3 | 1.62 Billion EUR | 25.04% |
| 2015 FY | 4.28 Billion EUR | -2.35% |
| 2015 Q1 | 1.02 Billion EUR | -23.6% |
| 2015 Q4 | 334 Million EUR | -79.48% |
| 2015 Q2 | 1.3 Billion EUR | 27.27% |
| 2014 Q2 | 777 Million EUR | -28.32% |
| 2014 Q1 | 1.08 Billion EUR | 2.65% |
| 2014 FY | 4.39 Billion EUR | 18.11% |
| 2014 Q3 | 1.19 Billion EUR | 53.15% |
| 2014 Q4 | 1.33 Billion EUR | 12.52% |
| 2013 Q2 | 448 Million EUR | -55.38% |
| 2013 Q1 | 1 Billion EUR | 144.88% |
| 2013 FY | 3.71 Billion EUR | -25.17% |
| 2013 Q4 | 1.05 Billion EUR | -12.94% |
| 2013 Q3 | 1.21 Billion EUR | 170.76% |
| 2012 Q4 | 410 Million EUR | -73.36% |
| 2012 FY | 4.96 Billion EUR | -12.75% |
| 2012 Q1 | 1.82 Billion EUR | 26.96% |
| 2012 Q3 | 1.53 Billion EUR | 33.48% |
| 2012 Q2 | 1.15 Billion EUR | -36.89% |
| 2011 FY | 5.69 Billion EUR | 4.13% |
| 2011 Q4 | 1.43 Billion EUR | -29.11% |
| 2011 Q1 | 1.21 Billion EUR | 178.72% |
| 2011 Q2 | 1 Billion EUR | -17.41% |
| 2011 Q3 | 2.03 Billion EUR | 101.79% |
| 2010 Q3 | 1.6 Billion EUR | -5.74% |
| 2010 FY | 5.46 Billion EUR | 3.84% |
| 2010 Q4 | 437 Million EUR | -72.84% |
| 2010 Q2 | 1.7 Billion EUR | -0.41% |
| 2010 Q1 | 1.71 Billion EUR | 41.77% |
| 2009 Q1 | 1.57 Billion EUR | 248.31% |
| 2009 FY | 5.26 Billion EUR | -26.73% |
| 2009 Q4 | 1.2 Billion EUR | -14.8% |
| 2009 Q3 | 1.41 Billion EUR | 33.99% |
| 2009 Q2 | 1.05 Billion EUR | -32.89% |
| 2008 Q1 | 1.86 Billion EUR | 42.58% |
| 2008 FY | 7.18 Billion EUR | 36.32% |
| 2008 Q4 | -1.06 Billion EUR | -156.36% |
| 2008 Q3 | 1.88 Billion EUR | 61.39% |
| 2008 Q2 | 1.16 Billion EUR | -37.21% |
| 2007 FY | 5.27 Billion EUR | 31.6% |
| 2007 Q3 | 1.29 Billion EUR | -2.51% |
| 2007 Q2 | 1.33 Billion EUR | 0.02% |
| 2007 Q1 | 1.33 Billion EUR | 63.4% |
| 2007 Q4 | 1.3 Billion EUR | 0.57% |
| 2006 Q2 | 869.46 Million EUR | -42.47% |
| 2006 FY | 4 Billion EUR | 77.57% |
| 2006 Q1 | 1.51 Billion EUR | 231.71% |
| 2006 Q4 | 815.45 Million EUR | 0.48% |
| 2006 Q3 | 811.59 Million EUR | -6.66% |
| 2005 Q2 | 542.63 Million EUR | -61.65% |
| 2005 Q4 | 455.63 Million EUR | -36.18% |
| 2005 Q3 | 713.99 Million EUR | 31.58% |
| 2005 Q1 | 1.41 Billion EUR | 159.95% |
| 2005 FY | 2.25 Billion EUR | 162.54% |
| 2004 Q1 | 568.16 Million EUR | 16.43% |
| 2004 FY | -3.6 Billion EUR | -274.06% |
| 2004 Q3 | -2.36 Billion EUR | -515.86% |
| 2004 Q2 | 568.14 Million EUR | -0.0% |
| 2004 Q4 | -2.35 Billion EUR | 0.11% |
| 2003 Q1 | 470.43 Million EUR | 1.18% |
| 2003 Q2 | 471.05 Million EUR | 0.13% |
| 2003 Q3 | 654.53 Million EUR | 38.95% |
| 2003 Q4 | 487.96 Million EUR | -25.45% |
| 2003 FY | 2.07 Billion EUR | 17.74% |
| 2002 Q3 | 461.77 Million EUR | 11.35% |
| 2002 Q2 | 414.71 Million EUR | 0.0% |
| 2002 FY | 1.76 Billion EUR | 11.05% |
| 2002 Q4 | 464.94 Million EUR | 0.69% |
| 2001 FY | 1.58 Billion EUR | 60.91% |
| 2000 FY | 985 Million EUR | 57.6% |
| 1999 FY | 625 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AstraZeneca PLC | 5.95 Billion USD | 9.32% |
| Bristol-Myers Squibb Company PFD CONV 2 | 8.02 Billion USD | 32.71% |
| CSPC Pharmaceutical Group Limited | 830.91 Million USD | -549.885% |
| Clarus Therapeutics Holdings, Inc. | -56.51 Million USD | 9655.493% |
| Novartis AG | 14.85 Billion USD | 63.636% |
| PT Kalbe Farma Tbk. | 179.7 Million USD | -2904.916% |